Lenalidomide plus dexamethasone effective in newly diagnosed myeloma
Kate Matthews
This article has no abstract so we have provided the first paragraph of the full text.
The thalidomide analog lenalidomide has more-potent preclinical activity than thalidomide, and is efficacious in patients with relapsed and refractory myeloma when used alone or in combination with dexamethasone; however, the efficacy of lenalidomide in previously untreated multiple myeloma patients has not been studied. In a phase II clinical trial, Rajkumar and co-workers investigated toxicity and response rates in previously untreated, newly diagnosed multiple myeloma patients treated with lenalidomide plus dexamethasone.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.